Brooks Laboratories Ltd

Brooks Laboratories Ltd has reached a new 52-week low of Rs.61.4, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors.

Brooks Laboratories Ltd touched a fresh 52-week low of Rs.62 today, marking a significant decline in its stock price amid ongoing challenges in its financial and market performance. The stock’s fall comes despite positive quarterly results, reflecting broader concerns about its long-term growth and valuation metrics.

Brooks Laboratories Ltd has reached a new 52-week low of Rs.62.68 today, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial and market performance over the past year.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Brooks Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.64.25 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance factors.

Brooks Laboratories Ltd has touched a new 52-week low of Rs.66 today, marking a significant decline amid a sustained downward trajectory. The stock’s performance continues to lag behind its sector and broader market indices, reflecting ongoing concerns about its financial metrics and market positioning.

Brooks Laboratories Ltd has touched a new 52-week low of Rs.66 today, marking a significant decline amid a sustained downtrend that has seen the stock lose nearly 16% over the past ten trading sessions.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Brooks Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.69 today, marking a significant decline amid an extended period of negative returns and underperformance relative to its sector and broader market indices.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Brooks Laboratories Ltd has reached a new 52-week low of Rs.69.05, marking a significant decline amid a prolonged downtrend. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial performance and valuation metrics.

Brooks Laboratories Ltd touched a fresh 52-week low of Rs.84.35 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its valuation and performance metrics.

Brooks Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.89.1 today, marking a significant milestone in its ongoing price decline. This level reflects a near 56% reduction from its 52-week high of Rs.202.8, underscoring the stock's challenging performance over the past year.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 24 December 2025, providing investors with the most up-to-date view of the company's fundamentals, returns, and technical outlook.

Brooks Laboratories has reached a new 52-week low, with its share price touching Rs.91.7 today. This marks a significant decline amid a broader market environment where the Sensex remains near its yearly highs, highlighting the stock's relative underperformance within the Pharmaceuticals & Biotechnology sector.

Brooks Laboratories has reached a new 52-week low of Rs.92.1, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a combination of subdued financial metrics and broader market dynamics.

Brooks Laboratories has reached a new 52-week low, with its stock price touching Rs.93.75 today. This marks a significant decline amid a broader market environment where the Sensex is trading near its yearly highs, highlighting the stock's underperformance within the Pharmaceuticals & Biotechnology sector.